Advising EcoPha Biotech on Its Current Capital Raise

NEW YORK, June 29, 2026. Keningford Partners announces that it is advising EcoPha Biotech on its current capital raise.

EcoPha Biotech is developing a proprietary process that produces both sustainable bioplastics and aviation fuel from a single non-edible feedstock, addressing two high-growth end markets without competing for food-grade agricultural inputs. The company's technology targets industrial-scale production of drop-in alternatives for packaging, materials, and sustainable aviation fuel (SAF) applications where regulatory pressure and corporate offtake commitments are accelerating demand.

EcoPha's flagship project, based in Queensland, Australia, is supported by government co-funding and sits at the center of a multi-jurisdiction capital structure involving cross-border SPV coordination. The company has established strategic partnerships across the aviation and industrial sectors, positioning the platform for institutional capital that understands both deep-tech process development and long-cycle infrastructure deployment.

The engagement reflects Keningford Partners' focus on growth-stage biotech and deep-tech mandates where capital structure, cross-border entity coordination, technology narrative, and investor positioning require senior-led attention from origination through close.

“What stood out working with Keningford is the level of attention on a mandate like ours, multiple SPVs, multiple geographies, a lot of moving pieces. Haktan took the time to actually understand the technology and the story before taking it to investors, which isn't something we'd experienced before. It's made the whole process feel far more credible.”

Dr. Wilson Ling, CEO, EcoPha Biotech

Keningford Partners works with a small number of companies each year on capital raises and strategic transactions, providing direct, senior-led access to institutional investors.